受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | E7080 mesylate | Storage (From the date of receipt) |
3 years -20°C powder | ||||||||
化学式 | C21H19ClN4O4.CH4O3S |
||||||||||
分子量 | 522.96 | CAS No. | 857890-39-2 | ||||||||
Solubility (25°C)* | 体外 | DMSO | 13 mg/mL (24.85 mM) | ||||||||
Water | Insoluble | ||||||||||
Ethanol | Insoluble | ||||||||||
体内 (毎回新しく調製した物を用意してください) |
|
||||||||||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | Lenvatinib Mesylate is a synthetic, orally available tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (Kit (c-Kit)), and rearranged during transfection (RET (c-RET)). Lenvatinib Mesylate has potential antineoplastic activity. |
---|---|
in vitro | E7080 is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. |
細胞アッセイ | 細胞株 | HUVECs |
---|---|---|
濃度 | 5.2 nM (SCF) & 5.1 nM (VEGF) | |
反応時間 | ||
実験の流れ | HUVECs were treated with various concentrations of E7080 for an hour and stimulated with either SCF or VEGF (20 ng/mL) for 5 min. |
|
動物実験 | 動物モデル | Female BALB/c nude mice |
投薬量 | 30 & 100 mg/kg | |
投与方法 | p.o. |
|
Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma [ Nat Commun, 2024, 15(1):1754] | PubMed: 38409200 |
Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma [ J Hepatocell Carcinoma, 2023, 10:697-712] | PubMed: 37138764 |
Lenvatinib inhibits intrahepatic cholangiocarcinoma via Gadd45a-mediated cell cycle arrest [ Discov Oncol, 2023, 14(1):26] | PubMed: 36821012 |
Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma [ Cancer Res, 2022, canres.2934.2021] | PubMed: 35767704 |
circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis [ Clin Transl Med, 2022, 12(1):e662] | PubMed: 35051313 |
EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli [ Cell Death Dis, 2022, 13(4):351] | PubMed: 35428350 |
Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis [ Sci Rep, 2022, 12(1):12546] | PubMed: 35869130 |
Regorafenib and reactive metabolite of sunitinib activate inflammasomes: Implications for multi tyrosine kinase inhibitor-Iiduced immune related adverse events [ Pharmazie, 2022, 77(2):54-58] | PubMed: 35209964 |
Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report [ Commun Med (Lond), 2022, 2:80] | PubMed: 35789568 |
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma [ J Immunother Cancer, 2021, 9(6)e002305] | PubMed: 34168004 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。